COVID-19, Multiple Sclerosis
Conditions
Brief summary
The aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.
Detailed description
Study objectives 1. To identify the incidence of upper respiratory tract symptoms: fever, cough and breathing difficulties, other symptoms suggestive of COVID-19 infection, respiratory tract infections suggestive of COVID-19, and COVID-19 confirmed by laboratory testing among the UK MS population 2. To establish if some DMDs increase the risk of COVID-19 infection 3. To determine the incidence and effectiveness of self-isolation in the MS population. To examine the impact self-isolation has on mood, fatigue, and other routinely collected patient reported outcome measures from the MS Register. 4. To determine the clinical outcome of respiratory tract infections, including confirmed and suspected cases of COVID-19, in terms of symptoms, time to recovery, hospital admission, requirement for ventilation, and death. 5. To determine the longer-term impact of COVID-19 on MS, using routinely collected MS outcomes in the MS register, including impact on disability, relapses and changes in DMDs as assessed at 3 monthly intervals. 6. To determine where people are obtaining their health information during the COVID-19 outbreak. 7. To establish changes in DMDs prior to and as a result of symptoms related and unrelated to COVID-19
Interventions
None listed
Sponsors
Swansea University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>18 and confirmed diagnosis of MS, enrolled on UK MS Register
Exclusion criteria
* None of the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of COVID-19 Infections within an MS Cohort in the UK | Through study completion, an average of 1 year | Targeted questionnaire dependent on COVID Status |
| Hospitalisations in MS Patients with COVID-19 | 1 Year (regular outputs) | Monitor admission rates in linked population |
| Mortality | 1 Year from study commencement | Death data from routinely reported government level data (HES/PEDW) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient Reported Expanded Disability Status Score | 1 year (at least 6 monthly) | Patient Reported Outcome for MS disability |
| Hospital Anxiety and Depression Scale | 1 year (at least 6 monthly) | Patient Reported Outcome for anxiety and depression |
| Multiple Sclerosis Impact Scale 29 V2 | 1 year (at least 6 monthly) | Patient Reported Outcome for Multiple sclerosis impact on physical and psychological status |
| Multiple Sclerosis Walking Scale 12 V2 | 1 year (at least 6 monthly) | Patient Reported Outcome for walking status |
| Fatigue Severity Scale | 1 year (at least 6 monthly) | Patient Reported Outcome for impact of fatigue |
| EuroQol 5D (3l) | 1 year (at least 6 monthly) | Patient Reported Outcome for general quality of life |
Countries
United Kingdom
Contacts
PRINCIPAL_INVESTIGATORRichard S Nicholas
Clinical Lead
PRINCIPAL_INVESTIGATORNikos Evangelou
Co-PI
Outcome results
None listed